NEXI-001

N/A

Report date: 2023/01/01 08:29:34

Base Information

Drug NameNEXI-001
Drug Alias Nameartificial antigen-presenting cell-based adoptive cell therapyanti-WT1/HLA-A0201 + anti-Prame/HLA-A0201 + anti-Cyclin A1/HLA-A0201 adoptive T-cell therapyadoptive T-cell therapyaAPC-based adoptive cell therapyNEXI-001
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeximmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesNeximmune IncNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A